drugset
drugset / Trial / NCT00115050

TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options

NCT00115050 ↗

Phase 3 Completed 260 enrolled Tibotec Pharmaceuticals, Ireland
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label safety study to provide early access to TMC114 for HIV-1 infected patients who have failed and exhausted regimens based on commercially available antiretroviral (ARV) therapy and who are ineligible for participation in any other Tibotec-sponsored trial.

Timeline

Start
2005-06
Primary completion
2007-06
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Darunavir Small molecule 600 mg Oral

Indications

HIV infectious disease